JP6158513B2 - タクソール／ステロイド化合物 - Google Patents

タクソール／ステロイド化合物 Download PDF

Info

Publication number
JP6158513B2
JP6158513B2 JP2012535616A JP2012535616A JP6158513B2 JP 6158513 B2 JP6158513 B2 JP 6158513B2 JP 2012535616 A JP2012535616 A JP 2012535616A JP 2012535616 A JP2012535616 A JP 2012535616A JP 6158513 B2 JP6158513 B2 JP 6158513B2
Authority
JP
Japan
Prior art keywords
taxol
steroid
compound
cholesterol
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012535616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509360A5 (https=
JP2013509360A (ja
Inventor
玉玲 対
玉玲 対
学軍 夏
学軍 夏
瑞芳 郭
瑞芳 郭
鵬宵 張
鵬宵 張
翠萍 周
翠萍 周
仁芸 汪
仁芸 汪
篶嘉 金
篶嘉 金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS and PUMC
Original Assignee
Institute of Materia Medica of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS and PUMC filed Critical Institute of Materia Medica of CAMS and PUMC
Publication of JP2013509360A publication Critical patent/JP2013509360A/ja
Publication of JP2013509360A5 publication Critical patent/JP2013509360A5/ja
Application granted granted Critical
Publication of JP6158513B2 publication Critical patent/JP6158513B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Epoxy Compounds (AREA)
JP2012535616A 2009-10-29 2010-10-28 タクソール／ステロイド化合物 Active JP6158513B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910236960.7A CN102048725B (zh) 2009-10-29 2009-10-29 紫杉醇胆固醇复合物
CN200910236960.7 2009-10-29
PCT/CN2010/078202 WO2011050735A1 (zh) 2009-10-29 2010-10-28 紫杉醇/类固醇复合物

Publications (3)

Publication Number Publication Date
JP2013509360A JP2013509360A (ja) 2013-03-14
JP2013509360A5 JP2013509360A5 (https=) 2017-01-12
JP6158513B2 true JP6158513B2 (ja) 2017-07-12

Family

ID=43921347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535616A Active JP6158513B2 (ja) 2009-10-29 2010-10-28 タクソール／ステロイド化合物

Country Status (9)

Country Link
US (1) US20130150335A1 (https=)
EP (1) EP2494956A4 (https=)
JP (1) JP6158513B2 (https=)
KR (1) KR20120091258A (https=)
CN (2) CN102048725B (https=)
AU (1) AU2010312017B2 (https=)
BR (1) BR112012010149A2 (https=)
CA (1) CA2779316C (https=)
WO (1) WO2011050735A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102048688B (zh) * 2009-10-29 2014-03-05 中国医学科学院药物研究所 以胆固醇复合物为中间载体的紫杉醇亚微乳
EP2679225A1 (de) * 2012-06-26 2014-01-01 Universitätsklinikum Freiburg Pharmazeutische Zusammensetzung mit synergistischer Wirkung von direkten Katalaseinhibitoren und zur Katalasezerstörung führenden Modulatoren des NO-Stoffwechsels oder der extrazellulären Superoxidanionenproduktion
US11273105B2 (en) * 2017-06-16 2022-03-15 Sorse Technology Corporation Method for preparing solid forms of plant extract
CN108272747B (zh) * 2018-03-16 2020-02-18 武汉百纳礼康生物制药有限公司 一种非那雄胺溶致液晶凝胶制剂前体及其制备方法
KR20210078505A (ko) 2018-10-16 2021-06-28 유에스 나노 푸드 앤 드럭 인코포레이티드 종양내 주사 제형
WO2021211294A1 (en) 2020-04-13 2021-10-21 US Nano Food & Drug INC Basic chemotherapeutic intratumour injection formulation
KR102789632B1 (ko) * 2021-04-01 2025-04-01 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
CN115177589B (zh) * 2021-04-07 2024-02-06 中国医学科学院药物研究所 一种紫杉醇脑靶向脂质体和其制备方法及应用
CN115463110B (zh) * 2021-06-10 2023-12-15 中国医学科学院药物研究所 一种胆酸修饰的口服紫杉醇纳米粒、其制备方法及应用
CN115737654B (zh) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN116196283A (zh) * 2021-11-30 2023-06-02 深圳玖星制药有限公司 一种注射用紫杉烷类药物脂质体冻干粉剂的制备方法及原料组方
CN117482052A (zh) * 2023-11-29 2024-02-02 中国药科大学 一种口服紫杉醇三元递药系统及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
CN1116875C (zh) * 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
CN101396343B (zh) * 2007-09-26 2011-12-07 中国医学科学院药物研究所 以脂质复合物为中间载体的紫杉醇亚微乳
CN102048688B (zh) * 2009-10-29 2014-03-05 中国医学科学院药物研究所 以胆固醇复合物为中间载体的紫杉醇亚微乳

Also Published As

Publication number Publication date
EP2494956A9 (en) 2013-04-17
CN102811706A (zh) 2012-12-05
CN102811706B (zh) 2015-05-06
AU2010312017B2 (en) 2014-07-17
CN102048725A (zh) 2011-05-11
US20130150335A1 (en) 2013-06-13
KR20120091258A (ko) 2012-08-17
EP2494956A1 (en) 2012-09-05
JP2013509360A (ja) 2013-03-14
WO2011050735A1 (zh) 2011-05-05
CA2779316C (en) 2016-05-03
EP2494956A4 (en) 2013-10-23
HK1179513A1 (zh) 2013-10-04
BR112012010149A2 (pt) 2018-03-20
CN102048725B (zh) 2014-07-16
CA2779316A1 (en) 2011-05-05
AU2010312017A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
JP6158513B2 (ja) タクソール／ステロイド化合物
CN104224711B (zh) 以类固醇复合物为中间载体的紫杉醇亚微乳
Chen et al. Formulation of 20 (S)-protopanaxadiol nanocrystals to improve oral bioavailability and brain delivery
Jing et al. A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel
Man et al. Improved oral bioavailability of myricitrin by liquid self-microemulsifying drug delivery systems
CN101703468A (zh) 维生素e油纳米乳制剂与制备方法
CN102429897B (zh) 一种提高桑色素口服生物利用度的药物组合物
El Said et al. Vilazodone-phospholipid mixed micelles for enhancing oral bioavailability and reducing pharmacokinetic variability between fed and fasted states
US11452705B2 (en) Oral drug delivery composition containing oxaliplatin and method for preparing same
CN104367549B (zh) 包载补骨脂素‑阿霉素复合纳米结构脂质载体制剂及其制备方法
Ding et al. Hydroxypropyl trimethyl ammonium chloride chitosan (HACC)-modified protein nanoparticles enhance docetaxel oral delivery and exhibit potent in vitro anti-tumor and macrophage-activating effects
CN102451176B (zh) 多西紫杉烷/类固醇复合物
Qiao et al. Polygonatum sibiricum polysaccharide-based novel triptolide delivery derived from classic compatibility principles in traditional Chinese medicine: Simultaneous renal protection and toxicity attenuation in diabetic nephropathy
CN102451157B (zh) 以类固醇复合物为中间载体的多西紫杉烷亚微乳
CN101548950B (zh) 雷公藤红素纳米脂质注射液及其制备方法
HK1179513B (en) Paclitaxel/steroidal complex
CN121796323A (zh) 一种槲皮万寿菊素自微乳及其制备方法
HK1175707B (en) Submicro emulsion of paclitaxel using steroid complex as intermediate carrier

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150402

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150601

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160923

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20161124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170608

R150 Certificate of patent or registration of utility model

Ref document number: 6158513

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250